• LAST PRICE
    6.6900
  • TODAY'S CHANGE (%)
    Trending Down-0.5100 (-7.0833%)
  • Bid / Lots
    6.6700/ 8
  • Ask / Lots
    6.6900/ 1
  • Open / Previous Close
    7.0400 / 7.2000
  • Day Range
    Low 6.6600
    High 7.1850
  • 52 Week Range
    Low 6.6600
    High 21.5000
  • Volume
    26,054
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 7.2
TimeVolumeEYPT
09:32 ET9257.1691
09:36 ET2007.18
09:39 ET4327.12
09:45 ET6007.1243
09:52 ET9347
09:56 ET2006.96
10:03 ET1007.01
10:06 ET2007.01
10:08 ET1007.03
10:14 ET1006.98
10:17 ET14856.93
10:19 ET1006.925
10:24 ET1416.9
10:26 ET5006.8899
10:30 ET1006.85
10:33 ET1006.88
10:48 ET3456.86
10:51 ET1006.88
11:00 ET28516.85
11:02 ET2006.86
11:04 ET1006.86
11:09 ET24186.82
11:11 ET1006.82
11:22 ET4006.81
11:24 ET2006.81
11:26 ET2006.79
11:27 ET1006.78
11:42 ET6006.76
11:51 ET9336.73
11:56 ET17326.675
11:58 ET3006.675
12:00 ET1006.68
12:05 ET10696.69
12:07 ET5006.685
12:09 ET1006.68
12:12 ET4006.69
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesEYPT
EyePoint Pharmaceuticals Inc
237.1M
-3.0x
---
United StatesSMTI
Sanara Medtech Inc
225.9M
-19.3x
---
United StatesMRNS
Marinus Pharmaceuticals Inc
237.7M
-2.4x
---
United StatesRPID
Rapid Micro Biosystems Inc
143.9M
-2.0x
---
United StatesRDY
Dr Reddy's Laboratories Ltd
8.4B
30.9x
+14.47%
United StatesESALY
Eisai Co Ltd
11.9B
66.2x
+4.01%
As of 2022-10-05

Company Information

Eyepoint Pharmaceuticals, Inc. is a pharmaceutical company. The Company’s lead product candidate, EYP-1901, combines a bioerodible formulation of its Durasert technology with vorolanib, a tyrosine kinase inhibitor (TKI), which has demonstrated anti-VEGF activity. The Company has two commercial products, YUTIQ and DEXYCU. YUTIQ is a non-erodible intravitreal implant containing fluocinolone acetonide (FA) lasting for up to 36 months and is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. YUTIQ utilizes its Durasert sustained-release drug delivery technology platform. DEXYCU is an indicated for the treatment of post-operative ocular inflammation. DEXYCU utilizes its Verisome drug-delivery technology. The Company is also advancing YUTIQ 50, a six-month treatment for non-infectious uveitis affecting the posterior segment of the eye, one of the causes of blindness under a supplemental new drug application (sNDA) strategy.

Contact Information

Headquarters
480 Pleasant St Ste B300WATERTOWN, MA, United States 02472-2468
Phone
617-926-5000
Fax
617-926-5050

Executives

Non-Executive Independent Chairman of the Board
Goran Ando
President, Chief Executive Officer, Director
Nancy Lurker
Chief Financial Officer
George Elston
Chief Operating Officer
Jay Duker
Senior Vice President, Chief Commercial Officer
Scott Jones

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$237.1M
Revenue (TTM)
$41.5M
Shares Outstanding
34.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.33
EPS
$-2.26
Book Value
$5.44
P/E Ratio
-3.0x
Price/Sales (TTM)
5.7
Price/Cash Flow (TTM)
---
Operating Margin
-174.67%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.